Figure 2.
PSMA as a potential therapeutic target for prostate cancer. PSMA is a transmembrane protein overexpressed in prostate cancer. The extracellular domain of PSMA is internalized after ligand binding, allowing intracellular delivery of conjugated therapeutic agents, such as actinium-225. PSMA, prostate-specific membrane antigen.